Condition: Mucormycosis in Hematologic Malignancies · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This clinical trial, a single-arm prospective study, aims to evaluate the efficacy and safety of liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole in treating adult patients with malignant hematological diseases complicated by mucormycosis. The primary objectives are to determine the proportion of patients achieving complete or partial resolution of mucormycosis symptoms and to identify prognostic factors influencing survival outcomes. Participants will receive the combination therapy, undergo regular monitoring of symptoms, adverse events, and disease progression via radiological and laboratory assessments, and complete follow-up visits to track long-term survival. The study will analyze composite response rates, treatment-related adverse events, and survival data to refine therapeutic strategies for this high-risk population.
This description comes directly from the study's public registry record.
Sizhou Feng, professor · +8618322098556 · szfeng@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| The Second Hospital of Dalian Medical University | Dalian, China | Not Yet Recruiting |
| The First Affiliated Hospital of Harbin Medical University | Harbin, China | Not Yet Recruiting |
| Shengjing Hospital of China Medical University | Shenyang, China | Not Yet Recruiting |
| The First Affiliated Hospital of China Medical University | Shenyang, China | Not Yet Recruiting |
| Tianjin First Central Hospital | Tianjin, China | Not Yet Recruiting |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | Tianjin, China | Recruiting |
| Second Hospital of Tianjin Medical University | Tianjin, China | Not Yet Recruiting |
| Tianjin Haihe Hospital | Tianjin, China | Not Yet Recruiting |
| Tianjin Union Medical Center of Nankai University | Tianjin, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07185503